Abstract:Abstract:Immunostimulating factor (ISTF) isolated from Actinobacillus actinomycetemcomitans which has been described previously, is distinct from lipopolysaccharide and induces proliferation of B cells. This study was undertaken to investigate whether ISTF might enhance the stimulation of other immune cells. Immunohistochemically, ISTF exhibited a profound stimulating effect on macrophages and dendritic cells as well as B cells in the spleen of BALB/c mice. ISTF was also recognized for its capacity to induce d… Show more
“…on days 3, 7 and 12, and anti-4-1BB mAb (3E1) was injected i.p. on days 7 and 12, while a control group received PBS and rat IgG ( 16 , 27 ). The tumor diameter was measured every 2–3 days, and the tumor volume (in mm 3 ) was calculated using a caliper.…”
Section: Methodsmentioning
confidence: 99%
“…The immunostimulatory factor (ISTF; 13 kDa) isolated from A. actinomycetemcomitans , has potent mitogenic activity on mouse B cells and human peripheral blood mononuclear cells ( 26 ). ISTF has been reported to stimulate macrophages and dendritic cells in the spleens of BALB/c mice and also has the ability to induce the direct activation of mouse macrophages to induce IL-6, TNF-α, nitric oxide and major histocompatibility complex (MHC) class II expression ( 27 ). In addition, ISTF is a proteinaceous material that directly induces the proliferation of B lymphocytes, but does not affect the proliferation of T lymphocytes, even in the presence of antigen-presenting cells (APCs) ( 26 ).…”
Section: Introductionmentioning
confidence: 99%
“…In the absence of co-stimulatory signals, antigen presentation induces T cell anergy, while co-stimulatory signals activate non-responding tumor-specific T cells ( 29 ). ISTF is expected to be highly active against APCs, and anticancer activity can be expected to be increased by the amplification of the overall immune response ( 27 ). Therefore, in the present study it was hypothesized that a combination of ISTF, promoting antigen presentation, and 4-1BB mAbs, stimulating T cell co-stimulation signals, could increase T cell activity to eradicate RCC.…”
To improve the potential treatment strategies of incurable renal cell carcinoma (RCC), which is highly resistant to chemotherapy and radiotherapy, the present study established a combination therapy with immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) to augment the antitumor response in a murine RCC model. ISTF isolated from Actinobacillus actinomycetemcomitans stimulates macrophages, dendritic cells and B cells to produce IL-6, TNF-α, nitric oxide and major histocompatibility complex class II expression. 4-1BB (CD137) is expressed in activated immune cells, including activated T cells, and is a promising target for cancer immunotherapy. The administration of anti-4-1BB mAbs promoted antitumor immunity via enhancing CD11c + CD8 + T cells. The CD11c + CD8 + T cells were characterized by high killing activity and IFN-γ-producing ability, representing a phenotype of active effector cytotoxic T lymphocytes. The present study showed that combination therapy with ISTF and anti-4-1BB mAbs promoted partial tumor regression with established RCC, but monotherapy with ISTF or anti-4-1BB mAbs did not. These effects were speculated to be caused by the increase in CD11c + CD8 + T cells in the spleen and tumor, and IFN-γ production. These insights into the effector mechanisms of the combination of ISTF and anti-4-1BB mAbs may be useful for targeting incurable RCC.
“…on days 3, 7 and 12, and anti-4-1BB mAb (3E1) was injected i.p. on days 7 and 12, while a control group received PBS and rat IgG ( 16 , 27 ). The tumor diameter was measured every 2–3 days, and the tumor volume (in mm 3 ) was calculated using a caliper.…”
Section: Methodsmentioning
confidence: 99%
“…The immunostimulatory factor (ISTF; 13 kDa) isolated from A. actinomycetemcomitans , has potent mitogenic activity on mouse B cells and human peripheral blood mononuclear cells ( 26 ). ISTF has been reported to stimulate macrophages and dendritic cells in the spleens of BALB/c mice and also has the ability to induce the direct activation of mouse macrophages to induce IL-6, TNF-α, nitric oxide and major histocompatibility complex (MHC) class II expression ( 27 ). In addition, ISTF is a proteinaceous material that directly induces the proliferation of B lymphocytes, but does not affect the proliferation of T lymphocytes, even in the presence of antigen-presenting cells (APCs) ( 26 ).…”
Section: Introductionmentioning
confidence: 99%
“…In the absence of co-stimulatory signals, antigen presentation induces T cell anergy, while co-stimulatory signals activate non-responding tumor-specific T cells ( 29 ). ISTF is expected to be highly active against APCs, and anticancer activity can be expected to be increased by the amplification of the overall immune response ( 27 ). Therefore, in the present study it was hypothesized that a combination of ISTF, promoting antigen presentation, and 4-1BB mAbs, stimulating T cell co-stimulation signals, could increase T cell activity to eradicate RCC.…”
To improve the potential treatment strategies of incurable renal cell carcinoma (RCC), which is highly resistant to chemotherapy and radiotherapy, the present study established a combination therapy with immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) to augment the antitumor response in a murine RCC model. ISTF isolated from Actinobacillus actinomycetemcomitans stimulates macrophages, dendritic cells and B cells to produce IL-6, TNF-α, nitric oxide and major histocompatibility complex class II expression. 4-1BB (CD137) is expressed in activated immune cells, including activated T cells, and is a promising target for cancer immunotherapy. The administration of anti-4-1BB mAbs promoted antitumor immunity via enhancing CD11c + CD8 + T cells. The CD11c + CD8 + T cells were characterized by high killing activity and IFN-γ-producing ability, representing a phenotype of active effector cytotoxic T lymphocytes. The present study showed that combination therapy with ISTF and anti-4-1BB mAbs promoted partial tumor regression with established RCC, but monotherapy with ISTF or anti-4-1BB mAbs did not. These effects were speculated to be caused by the increase in CD11c + CD8 + T cells in the spleen and tumor, and IFN-γ production. These insights into the effector mechanisms of the combination of ISTF and anti-4-1BB mAbs may be useful for targeting incurable RCC.
“…Increased expression of iNOS in inflamed periodontal tissues in humans [15] [16] and in experimental periodontitis in animal models [17] [18] have been documented, suggesting that oral bacteria, such as Aggregatibacter actinomycetemcomitans [19], inducing periodontal tissue destruction may be responsible for the increased periodontal tissue-derived iNOS expression. Indeed, A. actinomycetemcomitans induced the production of NO by both murine macrophages [20] [21] [22] [23] and splenocytes [24] as well as human osteoblasts [25]. The induction of immune response to A. actinomycetemcomitans in mice both in vivo and in vitro was regulated by NO [26] [27] [28] [29].…”
Objective: Colchicine induced a non-protective Th 2-like immunity in Aggregatibacter actinomycetemcomitans-stimulated murine immune response. The aim of the present study was to determine whether colchicine affects inducible nitric oxide synthase (iNOS) activity and nitric oxide (NO) production in A. actinomycetemcomitans-immunized mice. Materials and Methods: BALB/c mice were sham-immunized (group I) or immunized with heat-killed A. actinomycetemcomitans (group II-VII). Colchicine was injected intraperitoneally before (group III), on the same day of (group IV), or after (group V) the primary immunization and on the same day of (group VI) or after (group VII) the secondary immunization. In vitro, spleen cells from either sham-or heat-killed A. actinomycetemcomitan-immunized animals were cultured and stimulated with heat-killed A. actinomycetemcomitans in the presence or absence of colchicine with or without addition of L-arginine, Db-cAMP, forskolin or interferon-γ (IFN-γ). The levels of splenic iNOS activity and both serum and culture supernatant NO levels were assessed. Results: The results showed that colchicine did inhibit both splenic iNOS activity and serum NO levels only when the drug was injected at the same time as the immunization (group IV and VI). Splenic iNOS activity and NO levels on antigen-stimulated spleen cell cultures were also suppressed by colchicine, even in the presence of L-arginine, Db-AMP or forskolin. IFN-γ only partially restored iNOS activity and NO levels in the antigen and colchicine-treated spleen cell cultures. Conclusion: This study suggests, therefore, that colchicine may suppress the iNOS activity and NO production in A. actinomycetemcomitans-immunized mice in vivo and in vitro.
“…3 In particular, the pathogenesis of periodontitis might be explained by immune stimulation by periodontopathic bacteria, which induce large scale T cell activation, cytokine production and polyclonal B cell activation. 4 The N-terminal amino acid sequence of outer membrane protein Omp26 (202 aa) from Nontypeable Haemophilus influenzae has a revealed homology to a Yersinia enterocolitica OmpH, as well as homologies to Skp (17 kDa), OmpH, and Hip-1 proteins in Pasteurella multocida, Yersinia pseudotuberculosis, Escherichia coli and Salmonella enterica. 5 Seventeen kilodalton protein (Skp) has been characterized as a molecular chaperone that interacts with unfolded proteins as they emerge in the periplasm from the Sec translocation machinery.…”
Actinobacillus actinomycetemcomitans is a gram-negative, nonmotile coccobacillus bacterium that is associated with several human diseases, including endocarditis, meningitis, osteomyelitis, subcutaneous abscesses and periodontal diseases. A full-length Omp1-like protein gene from A. actinomycetemcomitans was cloned into a pQE30 vector and overexpressed in Escherichia coli BL21(DE3) cells. The protein revealed sequence homologies to Seventeen kilodalton proteins (Skp) from Pasteurella multocida and E. coli that have been characterized as periplasmic chaperones. This soluble Omp1-like protein was successfully purified to homogeneity for further folding and functional studies. The purity, identity, and conformation of the protein were determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis, matrix-assisted laser desorption ionization mass spectrometry, circular dichroism, fluorescence spectroscopic, and differential scanning calorimetric studies. We showed that the protein formed an oligomer larger than a tetramer. We found, further, that it is comprised of mostly α-helices and boasts high thermal stability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.